| 生物活性 |
Kv7.2/Kv7.3 activator-3 (GRT-X) is an orally active activator of Kv7.2/Kv7.3 and TSPO that activates Kv7.2/Kv7.3, Kv7.4, and Kv7.5 with EC50 values of 0.37, 2.06, and 0.75 μM, respectively, and binds TSPO with Ki values of 0.07 μM (rat membrane) and 4.60 μM (human U-118 MG cells), prevents motor neuron degeneration following exposure to conditioned medium from mouse and human amyotrophic lateral sclerosis/frontotemporal dementia astrocytes, stimulates dorsal root ganglion axon growth through TSPO and Kv7.2/3 activation, exhibits antiepileptic efficacy in seizure models, and alleviates hyperalgesia in patients with diabetic neuropathy, promotes neuronal survival and regeneration after cervical nerve injury in rats, and accelerates the recovery of normal function of sensory and motor neurons. |
体外研究 (In Vitro) |
Kv7.2/Kv7.3 activator-3 (6.25-25 μM,20 天) 可减少脊髓丘脑-上皮细胞 (SCOC) 中的运动神经元 (MN) 死亡。
Kv7.2/Kv7.3 activator-3 (0.1-10 μM,4 天) 在浓度高达 2.5 μM 时不会降低大鼠原代脊髓培养物 (VSCN) 中的 MN 存活率。
Kv7.2/Kv7.3 activator-3 (6.25-25 μM,4 天) 可维持经人 SOD1G93A-ACM/SOD1D90A-ACM/TDP43A90V-ACM 处理的 SCOCs 中的 MN 活力。
Kv7.2/Kv7.3 activator-3 (1-2.5 μM,4 天) 在用人 SOD1G93A-ACM/SOD1D90A-ACM/TDP43A90V-ACM 处理的 VSCNs 中可挽救 MN 死亡,并降低的 DCF 计数。
Kv7.2/Kv7.3 activator-3 (10 μM,4 天) 在胚胎 C57BL6/J DRG 中可增强神经突网络的长度和密度,并显著增加 AUC。
Kv7.2/Kv7.3 activator-3 (10 μM,8 天) 对轴突生长保持积极作用,并增加 E13.5 DRG 外植体的 AUC。
Kv7.2/Kv7.3 activator-3 (10 μM,4 天) 诱导参与髓鞘形成、雪旺细胞和神经元发育和分化以及轴突结构的基因表达增加。
Kv7.2/Kv7.3 activator-3 (10 μM,4 天) 在胚胎 TSPO-KO DRG 外植体中,对神经突生长没有影响,但会增加与髓鞘形成、雪旺细胞和神经元发育相关的基因表达,但不参与轴突结构的基因。
Kv7.2/Kv7.3 activator-3 在 CHO-K1 细胞中激活神经元 hKv7.2/3、hKv7.4 和 hKv7.5 通道,其效力高于瑞替加滨。
Kv7.2/Kv7.3 activator-3 (10 μM) 在培养的大鼠 DRG 神经元中可导致静息膜电位强效超极化 (EC50 = 0.201 μM,最大超极化:13.2 mV)。
Kv7.2/Kv7.3 activator-3 (10 μM) 在 TSPO 结合试验中,与大鼠心脏膜具有高亲和力结合,与人 U-118 MG 胶质母细胞瘤细胞具有中等亲和力结合;在 TSPO 功能试验中,可增强培养的大鼠 C6 胶质瘤细胞的孕烯醇酮合成。
Immunofluorescence
| Cell Line: |
SCOCs treated with SOD1G93A-ACM/SOD1D90A-ACM |
| Concentration: |
6.25 μM, 12.5 μM,25 μM |
| Incubation Time: |
4 days |
| Result: |
Preserved MN viability. |
RT-PCR
| Cell Line: |
E13.5 DRG explants |
| Concentration: |
10 μM |
| Incubation Time: |
4 days |
| Result: |
Induced a significant increase in the mRNA expression of TSPO, Kv7.2, Kv7.3, myelin-related genes (Mpz, Mbp and Plp), Dhh, Krox20 and CNPase, and increased the total mRNA expression levels of Tfap2α, Stmn2, Peripherin, Cad19, and Nfh genes. |
RT-PCR
| Cell Line: |
SPO-KO DRG explants |
| Concentration: |
10 μM |
| Incubation Time: |
4 days |
| Result: |
Increased Kv7.2, Kv7.3, Mpz, Mbp, Plp, Dhh, CNPase Tfap2α, and Cad19 mRNA levels, and decreased Stmn2 expression. |
|
体内研究 (In Vivo) |
Kv7.2/Kv7.3 activator-3 (10 mg/kg,口服,一次) 可提高 SD 大鼠模型中脑内神经甾体和类固醇的水平。
Kv7.2/Kv7.3 activator-3 (0-10 mg/kg,口服,一次) 可预防雄性 Wistar 大鼠最大电休克癫痫 (MES) 模型中强直性癫痫发作。
Kv7.2/Kv7.3 activator-3 (0-3 mg/kg,口服,一次) 可提高雄性 Wistar 大鼠电休克癫痫 (ECS) 模型中的癫痫发作阈值。
Kv7.2/Kv7.3 activator-3 (0-100 mg/kg,口服,一次) 可增加戊四氮 (PTZ) 癫痫雄性 Wistar 大鼠模型中阵挛性癫痫发作的潜伏期,降低强直性癫痫发作的发生率。
Kv7.2/Kv7.3 activator-3 (0-100 mg/kg,口服,一次) 可降低 PTZ 癫痫雄性 SD 大鼠模型中强直性惊厥的发生率。
Kv7.2/Kv7.3 activator-3 (0-10 mg/kg,口服,一次) 可降低雄性 Rj:DBA/2 小鼠模型的野跑性癫痫和阵挛性癫痫发作的发生率,并预防强直性癫痫发作和死亡。
Kv7.2/Kv7.3 activator-3 (0-100 mg/kg,口服,一次) 可预防雄性 NMRI 小鼠模型中的 6 Hz 癫痫发作。
Kv7.2/Kv7.3 activator-3 (0.316-10 mg/kg,口服,一次) 可减轻 Streptozotocin (STZ) (MS-Q80520) 诱发的慢性神经性疼痛 (CNP) SD 大鼠模型中的痛觉过敏。
Kv7.2/Kv7.3 activator-3 (5-10 mg/kg,口服,一次) 可促进神经元的存活和再生,加速重度颈脊神经压迫性损伤 SD 大鼠模型中感觉神经元和运动神经元正常功能的恢复。
| Animal Model: |
Male SD rat (200-230 g) model |
| Dosage: |
10 mg/kg |
| Administration: |
p.o., once |
| Result: |
Increased brain levels of neurosteroids, including 3α,5α-THP and 3α,5α-THDOC, increased 627% (pregnenolone), 107% (progesterone), 116% (5-α-dihydroprogesterone), 132% (3α,5α-THP), 4911% (deoxycorticosterone), 1333% (5α-deoxycorticosterone), and 1040% (3α,5α-THDOC), respectively in brain steroid levels. |
| Animal Model: |
MES seizure male Wistar rats (200-230 g) model |
| Dosage: |
0 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg |
| Administration: |
p.o., once |
| Result: |
Prevented the occurrence of tonic epileptic seizures, with an ED50 of 3.7 mg/kg. |
| Animal Model: |
ECS seizure male Wistar rats (200-230 g) model |
| Dosage: |
0 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg |
| Administration: |
p.o., once |
| Result: |
Increased seizure threshold. |
| Animal Model: |
PTZ seizure male Wistar rats (200-230 g) model |
| Dosage: |
0 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg |
| Administration: |
p.o., once |
| Result: |
Increased latency to clonic seizures, decreased the incidence of PTZ-induced tonic seizures with ED50 of 37 mg/kg. |
| Animal Model: |
PTZ seizure male SD rats (200-230 g) model |
| Dosage: |
0 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg |
| Administration: |
p.o., once |
| Result: |
Reduced incidence of tonic convulsions. |
| Animal Model: |
Male Rj:DBA/2 mice (12-15 g) model |
| Dosage: |
0 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg |
| Administration: |
p.o., once |
| Result: |
Reduced the incidence of wild-running and clonic seizures, and prevented tonic seizures and mortality. |
| Animal Model: |
Male NMRI mice (21-25 g) model |
| Dosage: |
0 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg |
| Administration: |
p.o., once |
| Result: |
Prevented 6-Hz seizures with an ED50 of 13 mg/kg. |
| Animal Model: |
STZ-induced (75 mg/kg) CNP SD rats |
| Dosage: |
0.316, 1.0, 10 mg/kg |
| Administration: |
p.o., once |
| Result: |
Reduced mechanical hyperalgesia. |
| Animal Model: |
SD rats model |
| Dosage: |
10 mg/kg |
| Administration: |
p.o., once |
| Result: |
Increased the synthesis of anti-hyperalgesic neurosteroids. |
| Animal Model: |
Severe cervical spinal nerve compression injury SD rats model |
| Dosage: |
5 mg/kg, 10 mg/kg |
| Administration: |
p.o., once |
| Result: |
Had neuroprotective and regenerative effects, accelerated and improved functional recovery after traumatic peripheral nerve injury. |
|